Dell Technologies Inc vs Summit Therapeutics Inc — how do they compare? Dell Technologies Inc trades at $480.8 (market cap $284.93B), while Summit Therapeutics Inc trades at $15.01 (market cap $12.06B). The key difference: Dell Technologies Inc is far larger — about 23.6× Summit Therapeutics Inc's market cap, and Dell Technologies Inc pays a 0.57% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DELL | SMMT | |
|---|---|---|
Market Cap | $284.93B | $12.06B |
Sector | Technology | Health |
52-Week High | $467.27 | $26.98 |
52-Week Low | $111.10 | $12.55 |
Enterprise Value | $304.51B | $11.39B |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Dell Technologies stock trades at $478.30, up 4.45% in the last session, reflecting strong momentum amid AI-driven server demand. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $4.86 surpassing the $2.96 forecast. The technical outlook is bullish, with the price above key moving averages, while fundamentals show revenue growth to $95.57 billion in 2025 and a net income margin of 6.28%.
The outlook remains positive given robust analyst sentiment, with a consensus price target of $503.76 implying upside. Key risks include valuation concerns at a P/E of 35.14 and potential margin pressure from memory shortages. Continued execution on AI server backlog and commercial PC refresh cycles are critical for sustained growth.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Trailing returns across standard periods
Latest headlines on both assets
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →